CEO Troy Wilson Buys $1.1M of Kura Oncology Stock
KURA sits 69% above its 52-week low of $6.95.
Summary
CEO Troy Wilson bought $1.1 million of Kura Oncology stock in an open-market purchase, increasing his stake and signaling confidence in the company's trajectory.
Key Events · Ownership and Investor Activity · KURA
-
CEO Open-Market Purchase
Troy Wilson, President and CEO, bought 100,000 shares at $11.12 for $1,112,000 on August 17, 2026.
-
Purchase via Trust
The shares were acquired indirectly through the One Fish Two Fish Revocable Trust.
-
Post-Transaction Holdings
Following the purchase, Wilson's total holdings stand at 379,194 shares.
-
Recent Positive Developments
The purchase follows strong Phase 1a data for darlifarnib and a 57% sequential increase in Q2 net product revenue.
Analysis · KURA · Life Sciences
President and CEO Troy Wilson purchased 100,000 shares at $11.12 for $1,112,000 on August 17, 2026. This is a direct open-market purchase, not an option exercise or tax event, signaling strong conviction from the company's top executive. The purchase comes amid positive clinical data and revenue growth, and follows a recent amendment to his employment agreement.
How filings like this one have moved
In the 30 days to Oct 18, 2026, 29.5% of the 1427 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KURA was trading at $11.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $6.95 to $12.49. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.